Autoscreen: An innovative e-health solution for early identification of Autism Spectrum Disorder Phase II

Autoscreen：用于早期识别自闭症谱系障碍第二阶段的创新电子健康解决方案

• 批准号: 10016847
• 负责人: Joshua W Wade
• 金额: $ 48.5万
• 依托单位: ADAPTIVE TECHNOLOGY CONSULTING, LLC
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-23 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10016847
• 关键词: 5 year old; Academy; Address; Age; Age-Months; Agreement; Ambulatory Care; American; Area; Behavior; Behavior Therapy; Behavioral; Benchmarking; Caregivers; Child; Child Behavior; Childhood; Classification; Clinical; Code; Communities; Complex; Data; Development; Diagnosis; Diagnostic; Dimensions; Early Diagnosis; Early Intervention; Early identification; Early treatment; Effectiveness; Electronic Health Record; Enhancement Technology; Evaluation; Family; Feedback; Guidelines; Health; Healthcare; Impairment; Individual; Instruction; Intervention; Interview; Knowledge; Life; Link; Longevity; Measures; Medical; Neurodevelopmental Disorder; Outcome; Parents; Pathway interactions; Pattern; Pediatrics; Performance; Phase; Positioning Attribute; Practice Guidelines; Predictive Value; Prevalence; Provider; Public Health; Questionnaires; ROC Curve; Reporting; Research; Resources; Risk; Sensitivity and Specificity; Social isolation; Specificity; Speed; Stress; Structure; Symptoms; System; Technology; Testing; Translating; Triage; Underserved Population; Unemployment; United States; Visit; Wait Time; Work; accurate diagnosis; autism spectrum disorder; autistic children; base; clinical Diagnosis; clinical care; communication behavior; cost; design; digital; disorder risk; eHealth; early screening; improved; improved outcome; indexing; innovation; instrument; interest; medical specialties; pediatrician; predictive modeling; prototype; screening; screening guidelines; service intervention; social communication; success; technological innovation; tool; usability

PROJECT SUMMARY Early accurate identification and treatment of young children with Autism Spectrum Disorder (ASD) represents a pressing public health and clinical care challenge. Given mounting evidence that early, accurate diagnosis of ASD is possible and that very young children who receive intervention can demonstrate substantial gains in functioning, current American Academy of Pediatrics practice guidelines endorse formal ASD screening at 18 and 24 months of age. Ideally, this recommended screening would translate into early diagnosis and treatment for most children. Unfortunately, large numbers of children are still not screened for ASD; waits for specialized diagnostic assessment can be very long; and the average age of diagnosis in the US remains between 4 to 5 years of age. Furthermore, groups from traditionally underserved communities are even more likely to be diagnosed at later ages. Delays in accurate diagnosis contribute to high levels of family stress and limit access to ASD behavioral intervention services, which are increasingly recognized as very important to children’s functioning. Continuing work initiated in our Phase I project, the current project rigorously tests “Autoscreen”—a digital tool for rapid screening, diagnostic triage, referral, and treatment engagement of young children within community pediatric settings, with an embedded focus on reaching underserved populations. This tool fuses advanced computational strategies with expert knowledge and tools for ASD screening/assessment in order to realize a commercial tool that not only provides support for enhanced, reimbursable screening across diverse communities, but also establishes a clear decision pathway for early, accurate diagnostic triage and meaningful engagement in early treatment. In Phase II, we will rigorously evaluate the validity and broader clinical utility of Autoscreen. If successful, this innovative product could identify and link children with ASD to meaningful interventions at younger ages. We believe that a substantial potential market for such a system exists, given that commonly used developmental screening instruments identify roughly 8% of children as showing developmental risks in first years of life. In this capacity, our tool will ultimately be designed as a practical, feasible, and reimbursable health-screening module for wide-scale use in community pediatric settings.

项目摘要 早期准确识别和治疗患有自闭症谱系障碍（ASD）的幼儿， 一个紧迫的公共卫生和临床护理挑战。鉴于越来越多的证据表明，早期，准确的诊断， ASD是可能的，接受干预的非常年幼的儿童可以在以下方面取得实质性进展： 功能，目前的美国儿科学会实践指南支持18岁时进行正式的ASD筛查 和24个月大。理想情况下，这种推荐的筛查将转化为早期诊断和治疗 对大多数孩子来说。不幸的是，大量的儿童仍然没有筛查ASD;等待专业的 诊断评估可能需要很长时间;在美国，诊断的平均年龄保持在4到5岁之间 岁的此外，来自传统上得不到充分服务的社区的群体更有可能被 在晚年诊断。准确诊断的延误导致家庭压力很大，并限制了获得治疗的机会 ASD行为干预服务，这是越来越多地被认为是非常重要的儿童的 功能在我们的第一阶段项目中开始的持续工作，目前的项目严格测试“自动筛选”-a 数字化工具，用于快速筛查、诊断分诊、转诊和治疗， 社区儿科环境，重点是覆盖服务不足的人群。这个工具保险丝 先进的计算策略与ASD筛查/评估的专家知识和工具， 实现一个商业工具，不仅为各种不同的增强型、可报销的筛查提供支持， 社区，而且还建立了一个明确的决策途径，早期，准确的诊断分流和有意义的 参与早期治疗。在第二阶段，我们将严格评估的有效性和更广泛的临床效用， 自动筛选。如果成功，这种创新产品可以识别并将ASD儿童与有意义的 在年轻时进行干预。我们认为，这种系统存在着巨大的潜在市场，因为 通常使用的发育筛查工具确定大约8%的儿童表现出发育不良， 生命最初几年的风险在这种能力下，我们的工具最终将被设计成一个实用的，可行的， 在社区儿科环境中广泛使用的可偿还健康筛查模块。

项目成果

Toward Novel Tools for Autism Identification: Fusing Computational and Clinical Expertise.

• DOI: 10.1007/s10803-020-04857-x
• 发表时间: 2021-11
• 期刊: Journal of autism and developmental disorders
• 影响因子: 3.9
• 作者: Corona LL;Wagner L;Wade J;Weitlauf AS;Hine J;Nicholson A;Stone C;Vehorn A;Warren Z
• 通讯作者: Warren Z